Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

BACKGROUND: Zibotentan (ZD4054) is a specific endothelin A (ET(A)) receptor antagonist being investigated for the treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomkinson, Helen, Kemp, John, Oliver, Stuart, Swaisland, Helen, Taboada, Maria, Morris, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070638/
https://www.ncbi.nlm.nih.gov/pubmed/21414193
http://dx.doi.org/10.1186/1472-6904-11-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070638/
https://www.ncbi.nlm.nih.gov/pubmed/21414193
http://dx.doi.org/10.1186/1472-6904-11-3

Ejemplares similares